Although France's Rhone-Poulenc had been rumored to be interested in making a counter bid for American Cyanamid, for which American Home Products has offered $8.5 billion (Marketletter August 8 and pages 24-25), the French firm says "we have no cash, not for this level of transaction," the Wall Street Journal reports.
R-P chairman Jean-Rene Fourtou is quoted as saying that "we would be more comfortable with smaller, more focused acquisitions because (a big purchase) encumbers the flexibility of the company," which already has a debt level higher than the industry norm, at some 50% of its equity value.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze